Chromatin Signaling and Neurological Disorders - 1st Edition - ISBN: 9780128137963

Chromatin Signaling and Neurological Disorders, Volume 7

1st Edition

Series Volume Editors: Olivier Binda
Hardcover ISBN: 9780128137963
Imprint: Academic Press
Published Date: 1st September 2018
Page Count: 544
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

Background

Preface

1. Chromatin and epigenetic signaling pathways

2. Non-pathologic neurological development

Neurodegenerative disorders

3. Spinal muscular atrophy

4. Triplet-Repeat Neurological Diseases

5. Amyotrophic Lateral Sclerosis

6. Charcot-Marie-Tooth disease

7. Parkinson's disease

8. Huntington's disease

9. Multiple Sclerosis

10. Ataxia Telangiectasia

11. Cockayne Syndrome neurodevelopmental disorders

Neurodevelopmental disorders

12. Angelman Syndrome and Prader-Willi Syndrome

13. Rett Syndrome

14. Rubinstein-Taybi Syndrome

15. Sotos Syndrome

16. ATRX

17. Fragile X syndrome and mental retardation

Neuropsychiatric disorders

18. Autism Spectrum Disorder and Asperger Syndrome

19. Schizophrenia

20. Gilles de la Tourette Syndrome

21. Alzheimer's disease (and other dementias)

22. Mood disorders

23. Attention deficit hyperactivity disorder (ADHD)

24. Obsessive compulsive disorder (OCD)


Description

Although the sequencing of the human genome was completed over a decade ago, the molecular mechanisms that regulate access to genetic information remain largely unknown. Chromatin signaling proposes that small protein domains recognise chemical modifications on the genome scaffolding histone proteins, facilitating the nucleation of enzymatic complexes that open up or shut down the access to genetic information, thereby regulating gene expression. Aberrant access to genetic information leads to pathologies ranging from cancer to age-related disease and neurological disorders. Chromatin Signaling and Neurological Disorders explores our current understanding of how chromatin signaling regulates access to genetic information, and how their aberrant regulation can contribute to neurological disorders.

Here, researchers, students, and clinicians will gain a strong grounding in the relationship between chromatin signaling and neurological disorders, and discover approaches to better interpret and employ new diagnostic studies and epigenetic-based therapies. A diverse range of chapters from international experts speaks to the basis of chromatin and epigenetic signaling pathways, as well as specific chromatin signaling factors that regulate spinal muscular atrophy, ulbospinal muscular atrophy, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, multiple sclerosis, Angelman syndrome, Rader-Willi syndrome, Fragile X syndrome, Asperger syndrome, schizophrenia, and Gilles De La Tourette syndrome among other disorders.

In addition to the basic science of chromatin signaling factors, each disease-specific chapter speaks to the translational or clinical significance of recent findings, and implications for the development epigenetics-based therapeutics. Common themes of translational significance are also identified across disease types, as well as future potential of chromatin signaling research.

Key Features

  • Explores our current understanding of how chromatin signaling regulates access to genetic information, and how aberrant regulation can contribute to neurological disorders
  • Examines specific chromatin signaling factors that regulate spinal muscular atrophy, ulbospinal muscular atrophy, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, multiple sclerosis, Angelman syndrome, Rader-Willi syndrome, Fragile X syndrome, Asperger syndrome, schizophrenia, and Gilles De La Tourette syndrome among other disorders
  • Chapter contributions from international experts speak to the clinical significance of recent findings and implications for the development of epigenetics-based therapeutics
  • Researchers, students, and clinicians will discover approaches to better interpret and employ new diagnostic studies that make use of chromatin signaling, and also better understand the mechanism-of-action of epigenetic-based therapies for treating neurological disorders

Readership

Translational researchers, clinicians and graduate students in genomic medicine, epigenetics, neurology, neuroscience, and neuropsychiatry interested in genetics and epigenetic basis of neurological disorders; life science researchers; developmental biologists; neurologists, psychiatrists, and other MD/clinicians; pharmacologists in industry and academia


Details

No. of pages:
544
Copyright:
© Academic Press 2019
Published:
Imprint:
Academic Press
Hardcover ISBN:
9780128137963

Ratings and Reviews


About the Series Volume Editors

Olivier Binda Series Volume Editor

Dr. Olivier Binda is a Principal Investigator at Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, England, specializing in epigenetics and gene expression as it relates to human disease. Dr. Binda co-edited Chromatin Signaling and Diseases (Elsevier 2016), a volume in Elsevier’s Translational Epigenetics series, and has published 20 scientific papers in such peer reviewed journals as the Journal of Biological Chemistry, Biochemistry, Epigenetics, Oncogene, Scientific Reports, and Stem Cell Research. In past positions he has served as a postdoctoral fellow at McGill University and Stanford University, and he completed his PhD in Biochemistry at McGill University in 2007.

Affiliations and Expertise

Principal Investigator, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK